1-2 of 2
Hideo Tanaka, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial

Hideo Tanaka, MD, PhD, Jun Imagawa, MD, PhD, Masaya Okada, MD, PhD, Hirohisa Nakamae, MD, PhD, Masayuki Hino, MD, PhD, Kazunori Murai, MD, PhD, Yoji Ishida, M.D., Ph.D., Takashi Kumagai, MD, PhD, Seiichi Sato, MD, Kazuteru Ohashi, MD, PhD, Hisashi Sakamaki, MD, PhD, Hisashi Wakita, MD, PhD, Nobuhiko Uoshima, MD, PhD, Yasunori Nakagawa, MD, Yosuke Minami, MD, PhD, Masahiro Ogasawara, MD, PhD, Tomoharu Takeoka, MD, Hiroshi Akasaka, MD, Satoshi Morita, PhD, Junichi Sakamoto, MD, PhD, Shinya Kimura, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3998.
https://doi.org/10.1182/blood.V122.21.3998.3998
Published: 2013
Journal Articles

Cell Death Mechanisms Induced by INNO-406, a Novel Tyrosine Kinase Inhibitor for Imatinib-Resistant Ph+ Leukemia.

Yuri Kamitsuji, MD, Souichi Adachi, MD, PhD, Motonobu Watanabe, MD, Hiroshi Matsubara, MD, Yasuhiro Mizushima, MD, Yoshimi Hiraumi, MD, Ken-Ichiro Watanabe, MD, PhD, Hideo Tanaka, MD, PhD, Junya Kuroda, MD, PhD, Eishi Ashihara, MD, PhD, Shinya Kimura, MD, PhD, Taira Maekawa, MD, Tatsutoshi Nakahata, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 2177.
https://doi.org/10.1182/blood.V108.11.2177.2177
Published: 2006